While hnRNPA2B1 can lower the glycolytic metabolism in gastric cancer cells, inhibit tumor growth and reduce liver metastasis, it also makes these cells more sensitive to the chemotherapy drug cisplatin (CDDP). This evidence concerns the gene HNRNPA2B1 and neoplasm.